Abstract
Bladder diseases are very common clinically and pathologically. Among them, bladder cancer is a major public health concern, particularly in men, with both high incidence and high mortality. Bladder cancer is the fourth most common cancer in adult males, surpassed only by prostate, lung, and colon cancers, and the eighth most common cause of death in males in the United States. Understanding normal bladder histology, benign abnormalities, cancer prevalence, and carcinogenesis is important for bladder disease diagnosis as well as for the effective management of bladder diseases. This chapter will explore bladder cancer incidence, carcinogenesis, and clinical management to provide a brief pathologic point of view and guide the reader for further interest of the subsequent chapters.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Global cancer observatory: cancer today. International agency for research on cancer. 2018. Available from: https://gco.iarc.fr/today. Cited 01 May 2020.
Richters A, Aben KKH, Kiemeney L. The global burden of urinary bladder cancer: an update. World J Urol. 2020;38(8):1895–1904.
Howlader N NA, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2017, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2017/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020.: National Cancer Institute. Bethesda, MD,; 2020.
Cancer Facts and Statistics. American cancer society Atlanta, GA: American cancer society; 2020.
Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21(6):392–401.
Droller MJ. Bladder cancer. J Urol. 1997;157(4):1266–7.
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4–34.
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41.
Lopez-Knowles E, Hernandez S, Malats N, Kogevinas M, Lloreta J, Carrato A, et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res. 2006;66(15):7401–4.
van Rhijn BW, Montironi R, Zwarthoff EC, Jobsis AC, van der Kwast TH. Frequent FGFR3 mutations in urothelial papilloma. J Pathol. 2002;198(2):245–51.
Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA. Activation of RAS family genes in urothelial carcinoma. J Urol. 2009;181(5):2312–9.
Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest. 2007;117(2):314–25.
Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. J Urol. 2003;170(5):1987–93.
Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005;5(9):713–25.
Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, et al. Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod Pathol. 2015;28(5):612–30.
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22.
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540–56.e25.
Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR. Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma. Cancer Res. 1999;59(14):3512–7.
Puzio-Kuter AM, Castillo-Martin M, Kinkade CW, Wang X, Shen TH, Matos T, et al. Inactivation of p53 and Pten promotes invasive bladder cancer. Genes Dev. 2009;23(6):675-80.
Guo CC, Czerniak B. Bladder Cancer in the Genomic Era. Arch Pathol Lab Med. 2019;143(6):695–704.
Hartmann A, Rosner U, Schlake G, Dietmaier W, Zaak D, Hofstaedter F, et al. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab Invest. 2000;80(5):709–18.
Hartmann A, Schlake G, Zaak D, Hungerhuber E, Hofstetter A, Hofstaedter F, et al. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res. 2002;62(3):809–18.
Humphray SJ, Oliver K, Hunt AR, Plumb RW, Loveland JE, Howe KL, et al. DNA sequence and analysis of human chromosome 9. Nature. 2004;429(6990):369–74.
Saran KK, Gould D, Godec CJ, Verma RS. Genetics of bladder cancer. J Mol Med (Berl). 1996;74(8):441–5.
Saran KK, Gould D, Godec CJ, Verma RS. Genetics of bladder cancer. J Mol Med (Berl). 1996;74(8):441–5.
Cheng L, Cheville JC, Neumann RM, Bostwick DG. Natural history of urothelial dysplasia of the bladder. Am J Surg Pathol. 1999;23(4):443–7.
Stoehr R, Hartmann A, Hiendlmeyer E, Murle K, Wieland W, Knuechel R. Oligoclonality of early lesions of the urothelium as determined by microdissection-supported genetic analysis. Pathobiology. 2000;68(4-5):165–72.
Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol. 1997;15(3):154-60 Esrig D, Freeman JA, Stein JP, Skinner DG. Early cystectomy for clinical stage T1 transitional cell carcinoma of the bladder. Semin Urol Oncol. 1997;15(3):154–60.
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 475–7.
Tanaka N, Kikuchi E, Matsumoto K, Miyajima A, Nakagawa K, Oya M. Frequency of tumor recurrence: a strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer. J Urol. 2011;185(2):450–5.
Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65.
McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, et al. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naive Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016;69(5):855–62.
Hsu FS, Su CH, Huang KH. A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma. J Immunol Res. 2017;2017:6940546.
Powles T, Smith K, Stenzl A, Bedke J. Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. Eur Urol. 2017;72(4):477–81.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Zhou, H., Guo, C.C., Ro, J.Y. (2021). Introduction to Urinary Bladder Pathology. In: Zhou, H., Guo, C.C., Ro, J.Y. (eds) Urinary Bladder Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-71509-0_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-71509-0_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-71508-3
Online ISBN: 978-3-030-71509-0
eBook Packages: MedicineMedicine (R0)